Business Context and Reporting Period
Company: ASP Isotopes Inc. (ASPI)
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2026
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) with ENDRA Life Sciences Inc. (ENDRA) and its subsidiary Noble Africa LLC (Noble). The transaction involves the merger of Noble with a subsidiary of ENDRA, resulting in Noble becoming a wholly-owned subsidiary of ENDRA. Concurrently, ASPI will contribute its equity interest in Renergen Limited to Noble.
Key Financial Metrics and Transaction Terms
- Investment Proceeds: Noble agreed to sell approximately 4,594,218 Class A Units and 3,054,185 Class B Units at $6.57 per unit, generating aggregate gross proceeds of approximately $50 million.
- Contribution: ASPI will contribute its equity interest in Renergen to Noble in exchange for 55,500,000 Class B Units of Noble.
- Voting Rights: Class B Common Stock (received by ASPI upon conversion) will entitle the holder to 10 votes per share on all matters submitted to ENDRA stockholders.
- Debt Facility: ASPI may provide loans to Renergen up to $200 million under a fifth addendum to the ASPI Term Loan Facility.
- Liquidity Condition: Closing is conditioned on ENDRA having cash equal to or greater than $3.8 million.
- Insider Participation: ASPI directors and officers subscribed to Class A Units of Noble with an aggregate estimated purchase price of approximately $750,005.
Material Changes and Structural Impacts
- Corporate Name Change: ENDRA will be renamed Noble Africa Inc. immediately prior to the Effective Time.
- Capital Structure: The company will establish two classes of common stock: Class A (1 vote per share) and Class B (10 votes per share). Class B shares are convertible to Class A and automatically convert upon transfer (except for permitted transfers).
- Board Composition: The post-closing Board is expected to consist of seven directors: one CEO Director, five designated by Noble, and one designated by ENDRA.
- Reverse Stock Split: ENDRA may implement a reverse stock split prior to closing to maintain Nasdaq listing standards.
Guidance, Risks, and Contingencies
- Closing Conditions: The merger is subject to stockholder approval, SEC effectiveness of the Form S-4 registration statement, Nasdaq listing approval, receipt of the $50 million investment proceeds, and consent from the U.S. International Development Finance Corporation (DFC).
- Termination Rights: The agreement may be terminated if closing does not occur by December 24, 2026, or if stockholder approval is not obtained.
- Forward-Looking Risks: Risks include failure to obtain necessary regulatory approvals, delays in funding (including DFC and Standard Bank SA), inability to complete Phase 1 and 2 of the Virginia Gas Project, and volatility in helium and LNG prices.
- Warrant Waiver: ENDRA stockholders who participated in the October 2025 private placement waived their right to repurchase warrants following a change of control.
Investor Verification Checklist
- Verify the status of the Form S-4 registration statement and the upcoming special meeting for stockholder approval.
- Confirm the receipt of the $50 million Noble Investment proceeds prior to closing.
- Monitor the U.S. DFC consent status regarding the Renergen Finance Agreement.
- Review the Reverse Stock Split ratio once approved by the Board to assess impact on share count and liquidity.
- Assess the $200 million loan facility terms and Renergen's ability to service this debt.
- Check for any updates on the Virginia Gas Project timeline and funding requirements.